The China Mail - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.67325
AFN 63.999745
ALL 83.250398
AMD 377.159929
ANG 1.790083
AOA 916.9998
ARS 1382.3505
AUD 1.449696
AWG 1.80125
AZN 1.695409
BAM 1.70594
BBD 2.013154
BDT 122.637848
BGN 1.709309
BHD 0.377515
BIF 2964
BMD 1
BND 1.290401
BOB 6.906447
BRL 5.193497
BSD 0.999512
BTN 95.111495
BWP 13.788472
BYN 2.972354
BYR 19600
BZD 2.010179
CAD 1.391525
CDF 2285.000157
CHF 0.799702
CLF 0.023467
CLP 926.610462
CNY 6.894697
CNH 6.887795
COP 3682.63
CRC 464.734923
CUC 1
CUP 26.5
CVE 95.875012
CZK 21.255603
DJF 177.71982
DKK 6.466502
DOP 60.098809
DZD 133.238132
EGP 54.517371
ERN 15
ETB 157.050114
EUR 0.865301
FJD 2.236694
FKP 0.758039
GBP 0.75605
GEL 2.69004
GGP 0.758039
GHS 10.9998
GIP 0.758039
GMD 73.999913
GNF 8775.000005
GTQ 7.64789
GYD 209.174328
HKD 7.84015
HNL 26.604398
HRK 6.521299
HTG 131.185863
HUF 333.98978
IDR 16949.3
ILS 3.15655
IMP 0.758039
INR 93.48455
IQD 1310
IRR 1315874.999986
ISK 124.090168
JEP 0.758039
JMD 158.129555
JOD 0.709037
JPY 158.770105
KES 130.000308
KGS 87.449728
KHR 4009.999698
KMF 428.495038
KPW 899.974671
KRW 1504.669993
KWD 0.30953
KYD 0.832908
KZT 476.211659
LAK 21950.00036
LBP 89509.104995
LKR 315.318459
LRD 183.675007
LSL 17.069667
LTL 2.95274
LVL 0.60489
LYD 6.404975
MAD 9.342503
MDL 17.701369
MGA 4177.999863
MKD 53.342853
MMK 2099.498084
MNT 3571.008867
MOP 8.070843
MRU 40.109985
MUR 47.119596
MVR 15.469396
MWK 1737.000313
MXN 17.93386
MYR 4.049001
MZN 63.950207
NAD 17.070162
NGN 1385.730126
NIO 36.729977
NOK 9.688099
NPR 152.178217
NZD 1.741235
OMR 0.384474
PAB 0.999507
PEN 3.495979
PGK 4.389672
PHP 60.393032
PKR 279.191108
PLN 3.71335
PYG 6474.685228
QAR 3.643985
RON 4.413001
RSD 101.656005
RUB 81.298695
RWF 1460
SAR 3.752978
SBD 8.042037
SCR 14.05702
SDG 600.999874
SEK 9.469898
SGD 1.285897
SHP 0.750259
SLE 24.550373
SLL 20969.510825
SOS 571.505345
SRD 37.374033
STD 20697.981008
STN 21.725
SVC 8.746053
SYP 110.555055
SZL 17.070278
THB 32.610303
TJS 9.580319
TMT 3.51
TND 2.930302
TOP 2.40776
TRY 44.469755
TTD 6.790468
TWD 31.952024
TZS 2588.311
UAH 43.911606
UGX 3762.887497
UYU 40.550736
UZS 12195.499903
VES 473.27785
VND 26340
VUV 120.343344
WST 2.769273
XAF 572.15615
XAG 0.013308
XAU 0.000214
XCD 2.70255
XCG 1.801363
XDR 0.710952
XOF 570.501861
XPF 104.049913
YER 238.649671
ZAR 16.937302
ZMK 9001.198901
ZMW 19.105686
ZWL 321.999592
  • RBGPF

    -13.5000

    69

    -19.57%

  • CMSC

    -0.4028

    21.9

    -1.84%

  • AZN

    3.3400

    197.22

    +1.69%

  • GSK

    0.9600

    55.19

    +1.74%

  • NGG

    0.9100

    84.6

    +1.08%

  • BTI

    0.2100

    58.47

    +0.36%

  • RIO

    4.4700

    93.29

    +4.79%

  • CMSD

    -0.4000

    22.1

    -1.81%

  • BCE

    0.0100

    25.24

    +0.04%

  • BCC

    0.9000

    75.85

    +1.19%

  • RELX

    0.4000

    33.15

    +1.21%

  • BP

    -0.3500

    47

    -0.74%

  • RYCEF

    0.7600

    15.05

    +5.05%

  • JRI

    0.3800

    12.3

    +3.09%

  • VOD

    0.3200

    15.02

    +2.13%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

N.Wan--ThChM